<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Eight patients with various <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> were treated with <z:chebi fb="5" ids="28830">chlorambucil</z:chebi>, an analogue of <z:chebi fb="0" ids="28925,37598">nitrogen mustard</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>Five patients with CLL, 2 patients with malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and one each with <z:e sem="disease" ids="C0221269" disease_type="Disease or Syndrome" abbrv="">pseudolymphoma</z:e> of the lung and <z:e sem="disease" ids="C0024419" disease_type="Neoplastic Process" abbrv="">primary macroglobulinemia</z:e> were given 4-6 mg of <z:chebi fb="5" ids="28830">chlorambucil</z:chebi> per day for 1-2 weeks at 2-4 week intervals or a daily dose of 6 mg continuously </plain></SENT>
<SENT sid="2" pm="."><plain>Two cases of CLL and one each of follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and <z:e sem="disease" ids="C0221269" disease_type="Disease or Syndrome" abbrv="">pseudolymphoma</z:e> achieved partial remission </plain></SENT>
<SENT sid="3" pm="."><plain>Side effects included <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e>, especially <z:hpo ids='HP_0001882'>leukopenia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="5" ids="28830">Chlorambucil</z:chebi> can be used orally without severe toxicity for longer periods and the major indication for this drug seems to be CLL and favorable type of malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
</text></document>